Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer
- Author(s)
- Bagguley, D; Ong, S; Buteau, JP; Koschel, S; Dhiantravan, N; Hofman, MS; Emmett, L; Murphy, DG; Lawrentschuk, N;
- Details
- Publication Year 2021-06,Volume 17,Issue #17,Page 2225-2241
- Journal Title
- Future Oncology
- Publication Type
- Review
- Abstract
- Prostate-specific membrane antigen (PSMA) PET/CT is a novel imaging technique for the detection and staging of either primary or recurrent prostate cancer. Early studies demonstrated its improved sensitivity and specificity over and in combination with other currently employed imaging techniques, such as multiparametric MRI, bone scan, PET and CT. However, the lack of strength and confidence in these studies has meant incorporation of PSMA PET/CT into clinical guidelines and practice has been limited to date. In response, a number of high-quality prospective studies have recently emerged and reflect exciting results seen in preceding publications. Here we recount some of the key earlier publications, report results from the latest studies and look to the future discussing some of the eagerly awaited ongoing clinical trials.
- Keywords
- Antigens, Surface/*metabolism; Glutamate Carboxypeptidase II/*metabolism; Humans; Image Processing, Computer-Assisted; Male; Neoplasm Staging; Positron Emission Tomography Computed Tomography/*methods; Prostatic Neoplasms/*classification/*diagnosis/diagnostic imaging/metabolism; Pet/ct; Psma; diagnosis; imaging; prostate cancer; staging; urology
- Department(s)
- Surgical Oncology; Cancer Imaging
- PubMed ID
- 33724868
- Publisher's Version
- https://doi.org/10.2217/fon-2020-1293
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-05-23 08:14:03
Last Modified: 2025-05-23 08:15:07